Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment
Cancer Res 2020 Nov 15;80(22)5098-5108, E Subramani, M Radoul, C Najac, G Batsios, AR Molloy, D Hong, AM Gillespie, RD Santos, P Viswanath, JF Costello, RO Pieper, SM RonenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.